BIOGEN IDEC INC. Form S-8 POS July 22, 2008

Table of Contents

As filed with the Securities and Exchange Commission on July 22, 2008

Registration No. 333-128339

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

BIOGEN IDEC INC.

(Exact name of registrant as specified in its charter)

Delaware

33-0112644

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

14 Cambridge Center Cambridge, Massachusetts 02142

(Address of principal executive offices, including zip code)

BIOGEN IDEC INC. 2008 OMNIBUS EQUITY PLAN BIOGEN IDEC INC. 2005 OMNIBUS EQUITY PLAN

(Full title of the plan)

SUSAN H. ALEXANDER, ESQ.
Executive Vice President, General Counsel and Secretary
Biogen Idec Inc.
14 Cambridge Center
Cambridge, Massachusetts 02142
(617) 679-2000

(Name, address and telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer b Accelerated filer o Non-accelerated filer o Smaller reporting company o (Do not check if a smaller reporting company)

Table of Contents

EXPLANATORY NOTE

This post-effective amendment is being filed because the following shares that were previously reserved for issuance pursuant to the Biogen Idec Inc. 2005 Omnibus Equity Plan (the 2005 Plan) may now be issued pursuant to the Biogen Idec Inc. 2008 Omnibus Equity Plan (the 2008 Plan): (1) shares that remained available for grant under the 2005 Plan as of the effective date of the 2008 Plan (including shares available under such plan by reason of a predecessor plan) and (2) shares that were subject to awards under the 2005 Plan as of the effective date of the 2008 Plan but which remain unvested upon the cancellation, surrender, exchange or termination of such awards for any reason whatsoever.

TABLE OF CONTENTS

PART II

Item 8. Exhibits

EXHIBIT INDEX

Ex-5 Opinion of Ropes & Gray LLP

Ex-23.1 Consent of PricewaterhouseCoopers LLP

Table of Contents

PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

The exhibits listed on the Exhibit Index immediately preceding such exhibits are filed as part of this Registration Statement.

Table of Contents

SIGNATURES AND POWER OF ATTORNEY

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on July 22, 2008.

BIOGEN IDEC INC.

By: /s/ James C. Mullen
James C. Mullen
Chief Executive Officer and President

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment has been signed by the following persons in the capacities indicated on July 22, 2008.

Further, we, the undersigned officers and directors of the Registrant hereby severally constitute and appoint James C. Mullen, Paul J. Clancy and Susan H. Alexander and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities as indicated, any and all amendments or supplements to the Registration Statement on Form S-8 of the Registrant to which this Post-Effective Amendment relates, including post-effective amendments to the Registration Statement, and generally to do all such things in connection therewith in our name and on our behalf in our capacities as indicated to enable the Registrant to comply with the provisions of the Securities Act of 1933 and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys or any of them, to any and all amendments.

Capacity Name /s/ James C. Mullen Director, Chief Executive Officer and President James C. Mullen (Principal Executive Officer) Executive Vice President and Chief Financial Officer /s/ Paul J. Clancy Paul J. Clancy (Principal Financial Officer) /s/ Michael F. MacLean Senior Vice President, Finance and Chief Accounting Officer Michael F. MacLean (Principal Accounting Officer) /s/ Bruce R. Ross Director and Chairman of the Board of Directors Bruce R. Ross Director Lawrence C. Best

Table of Contents

Name		Capacity
/s/ Marijn E. Dekkers	Director	
Marijn E. Dekkers		
/s/ Alan B. Glassberg	Director	
Alan B. Glassberg		
/s/ Nancy L. Leaming	Director	
Nancy L. Leaming		
/s/ Robert W. Pangia	Director	
Robert W. Pangia		
/s/ Stelios Papadopoulos	Director	
Stelios Papadopoulos		
/s/ Cecil B. Pickett	Director	
Cecil B. Pickett		
/s/ Lynn Schenk	Director	
Lynn Schenk		
/s/ Phillip A. Sharp	Director	
Phillip A. Sharp		
/s/ William D. Young	Director	
William D. Young		

Table of Contents

EXHIBIT INDEX

Exhibit	Description
5 +	Opinion of Ropes & Gray LLP.
23.1 +	Consent of PricewaterhouseCoopers LLP, an independent registered public accounting firm.
23.2 +	Consent of Ropes & Gray LLP (included in its opinion in Exhibit 5).
24 +	Powers of Attorney (contained in Part II hereof under Signatures and Power of Attorney).

+ Filed herewith.